- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06271733
TMS for Veterans Attending a 2-week Intensive Outpatient Program for PTSD
Intensive PTSD Treatment Combined With Transcranial Magnetic Stimulation: A Randomized Controlled Study
Study Overview
Detailed Description
Despite the efficacy of many evidence-based treatments for psychiatric disorders, a large percentage of treatment completers maintain their diagnosis and symptoms after treatment. For veterans with PTSD, approximately 66% of all individuals who successfully complete an evidence-based treatment retain their PTSD diagnosis.
An intervention that has been shown to be effective for non-response to first-line psychotherapies is transcranial magnetic stimulation (TMS). TMS is a safe, noninvasive intervention that uses a magnetic field to modulate cortical activity in brain areas linked to an overactive stress response. When compared to sham conditions which resembles the TMS condition but does not utilize any magnetic fields (i.e., proposed active ingredient), TMS has been associated with reduced depressive symptoms in treatment non-responders. Although the bulk of research examines TMS as a treatment for major depressive disorder, TMS has also shown promise in reducing symptoms of other psychiatric disorders such as PTSD.
In prior research TMS was associated with medium to large reductions in core PTSD symptoms when compared to sham conditions. Symptom reductions achieved via TMS have been demonstrated to persist. A recent study compared Cognitive Processing Therapy (CPT) combined with TMS to CPT with a sham condition and found that CPT combined with TMS was associated with greater PTSD symptom reductions during treatment and at six-month follow-up than CPT combined with a sham condition. This finding suggests that TMS may be beneficial as an augmentation to CPT. However, to our knowledge, previous literature has not yet examined whether TMS improves outcomes for individuals who are likely to not respond to CPT treatment.
Due to the demand for briefer TMS protocols, theta burst stimulation (iTBS) is a variation on TMS. Studies have found iTBS to be more efficient than standard TMS but still associated with significant improvements and low side effects in both depression and PTSD. The present study will utilize the more efficient iTBS protocol applied to the right dorsolateral prefrontal cortex (DLPFC) in order to reduce the length of stay for the participants.
Roughly one in four participants who complete Cognitive Processing Therapy (CPT) in the 2-week intensive outpatient program (IOP) at the Road Home Program at Rush do not report a meaningful reduction in PTSD symptoms and can be classified as non-responders. The present study seeks to determine whether adding iTBS to standard IOP programming reduces PTSD symptoms to a greater extent than adding a sham condition among participants who have not reported reduced symptoms by the end of the first week of treatment (i.e., likely non-responders). The present study will compare the two conditions at both post-treatment, 1- and 3-month follow-up.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Veterans or service members between the ages of 18 and 65 who are attending the 2- week Intensive Outpatient Program at the Road Home Program and have not had significant PTSD symptom change based on the PCL-5 during the first week of treatment.
- Participants with an HDRS-21 score ≤ 26 at screening visit
Exclusion Criteria:
Individuals with implants and non-removable metals which prevent them from safely receiving TMS, including:
- Aneurysm clips or coils
- Stents in the head, neck, or brain
- Deep brain stimulators
- Metallic implants in the head, neck, or brain (braces and dental implants do not interfere and are safe for TMS)
- Shrapnel or bullet fragments in or near the head
- Facial tattoos with metallic or magnetic-sensitive ink
- Other metal devices or ferromagnetic objects implanted in or near the head
- Pacemakers, intra-cardiac lines, or implanted medical pumps
- Individuals with a history of seizures or epilepsy (except those therapeutically induced by ECT)
- Individuals diagnosed with major, chronic mental health illnesses such as Psychotic Disorders, Bipolar Disorders, and Obsessive Compulsive Disorder
- Individuals with a history of substance abuse within the past six months
- Individuals with significant neurological disorders such as Parkinson's disease, Huntington's chorea, and Multiple sclerosis
- Individuals with unstable physical disease, such as unstable cardiac diseases
- Individuals currently on Benzodiazepine at a dose higher than 3mg or Lorazepam or equivalent.
- Women who are breastfeeding or pregnant
- Individuals with previous TMS treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Sham
|
2 sessions per day for 5 days of sham condition
|
Active Comparator: Active TMS
|
2 sessions of iTBS per day for 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PTSD Checklist for DSM-5 (PCL-5)
Time Frame: Baseline, 1 month follow up
|
Measure of PTSD symptom severity
|
Baseline, 1 month follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline, 1 month follow up
|
Measure of depression symptom severity
|
Baseline, 1 month follow up
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 21110503
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
Imperial College Healthcare NHS TrustImperial College LondonRecruiting
-
VA Office of Research and DevelopmentUniversity of California, San DiegoRecruiting
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Active, not recruiting
-
Oregon Health and Science UniversityEnrolling by invitation
-
VA Office of Research and DevelopmentCompleted
-
VA Office of Research and DevelopmentPortland VA Medical CenterActive, not recruiting
-
VA Office of Research and DevelopmentSan Diego Veterans Healthcare SystemCompleted
-
Creighton UniversityCompleted
-
VA Eastern KansasTerminated
Clinical Trials on TMS
-
Hartford HospitalRecruiting
-
Carilion ClinicUnknown
-
University of Southern CaliforniaNot yet recruitingBinge-Eating Disorder
-
Emory UniversityCompleted
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedExecutive FunctionUnited States
-
Bayside HealthNational Health and Medical Research Council, AustraliaCompletedMajor Depressive DisorderAustralia
-
Bayside HealthCompleted
-
National Institute of Mental Health (NIMH)Recruiting
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedExecutive FunctionUnited States
-
BeerYaakov Mental Health CenterCompletedSmoking | Chronic Obstructive Pulmonary DiseaseIsrael